Last reviewed · How we verify
Haemophilus Parainfluenzae Bronchitis
Approved treatments
- Ceftin · GSK
Ceftin works by inhibiting the bacterial enzyme responsible for cell wall synthesis, ultimately leading to bacterial cell death. - ALATROFLOXACIN · Pfizer
- Omnicef
- Sparcin
- Zinacef · GSK
Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death. - Noroxin
- Floxin
- Levaquin · Generic (originally Daiichi Sankyo/J&J)
Levofloxacin is a fluoroquinolone antibacterial agent. - Ofloxacine · Assistance Publique - Hôpitaux de Paris
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Haemophilus Parainfluenzae Bronchitis patent landscape — cliff calendar, originator estates, attackable patents
- Haemophilus Parainfluenzae Bronchitis treatment landscape brief
- Haemophilus Parainfluenzae Bronchitis treatment updates RSS
Frequently asked questions about Haemophilus Parainfluenzae Bronchitis
What drugs treat Haemophilus Parainfluenzae Bronchitis?
Tracked treatments include Ceftin, ALATROFLOXACIN, Omnicef, Sparcin, Zinacef, Noroxin, Floxin, Levaquin.
What is the treatment for Haemophilus Parainfluenzae Bronchitis?
Standard treatment for Haemophilus Parainfluenzae Bronchitis includes Ceftin, ALATROFLOXACIN, Omnicef, Sparcin, Zinacef. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Haemophilus Parainfluenzae Bronchitis patent cliff · Haemophilus Parainfluenzae Bronchitis CI report
- Treatment: Ceftin · GSK
- Treatment: ALATROFLOXACIN · Pfizer
- Treatment: Omnicef
- Treatment: Sparcin
- Treatment: Zinacef · GSK
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing